Abstracts 2007
General Information
Abstracts that have been selected for poster presentation have been divided into seven sessions:
- Session 1: Vaccination Strategies
- Session 2: Monitoring of Immune responses
- Session 3: Targets
- Session 4: Dendritic Cells
- Session 5: Antibodies
- Session 6: Adoptive Transfer, Mediators & Cytokines
| |
Session 1 | Session 2 | Session 3 |
|---|---|---|---|
| Title | Vaccination Strategies | Monitoring of Immune responses | Targets |
| Date Time |
12.04.2007 14.15 |
13.04.2007 14.00 |
13.04.2007 14.00 |
| Chaired by | M. Schmitt (Ulm) | H. Veelken (Freiburg) | S. Stevanovic (Tübingen) |
|
P01
P05 P06 P20 P23 P33 P41 P47 P56 P58 |
P07 P08 P13 P16 P34 P35 P36 P37 P40 P46 P48 P61 P62 |
P03 P04 P15 P17 P24 P28 P31 P38 P43 P45 P53 P60 |
| |
Session 4 | Session 5 | Session 6 |
|---|---|---|---|
| Title | Dendritic Cells | Antibodies | Adoptive Transfer, Mediators & Cytokines |
| Date Time |
12.04.2007 14.00 |
13.04.2007 14.00 |
12.04.2007 14.15 |
| Chaired by | E. Schultz (Marburg) | M. Gramatzki (Kiel) |
M. Herr (Mainz) |
|
P11 P19 P22 P25 P26 P27 P30 P42 P50 P52 |
P12 P18 P21 P32 P44 P57 |
P02 P09 P10 P14 P29 P39 P49 P51 P54 P55 P59 P63 |
List of poster presentations:
| P01 | Upregulation of antigen processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation W. Łuczyński, O. Kowalczuk, E. Iłendo, A. Stasiak-Barmuta, M. Krawczuk-Rybak |
| P02 | First force spectroscopy measurements of physiologic VLA-4 integrin activation by the chemokine SDF-1 at the single-molecule level on a living cell R. H. Eibl, M.D. |
| P03 | Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface A. O. Weinzierl, C. Lemmel, O. Schoor, M. Müller, T. Krüger, D. Wernet, J. Hennenlotter, A. Stenzl, K. Klingeln, H.-G. Rammensee and S. Stevanović |
| P04 | Melanoma-associated chondroitin sulphate proteoglycan (MCSP): a promising target antigen for cancer immunotherapy? C. Erfurt, I. Haendle, K. Thielemans, P. van der Bruggen, G. Schuler and E. S. Schultz |
| P05 | Regression of pancreatic carcinoma by intratumoral injection of a streptoccal lysate in mice C. Maletzki, M. Linnebacher, B. Kreikemeyer, F. Charrier, J. Emmrich |
| P06 | Cancer Immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen J. Fensterle, W. Goebel, C. Hotz, S. R. Meyer, U. R Rapp and I. Gentschev |
| P07 | Cellular immune responses against the cancer testis antigen SPAN-XB in healthy donors and patients with multiple myeloma C. Frank, M. Hundemer, A. D. Ho, H. Goldschmidt and M. Witzens-Harig |
| P08 | High Frequency of T Regulatory Cells in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Is Decreased by Thalidomide and Fludarabine Treatment K. Giannopoulos, M. Schmitt, P. Własiuk, J. Chen, A. Bojarska-Junak, M. Kowal, J. Roliński and A. Dmoszyńska |
| P09 | The CCR5Δ32 gene polymorphism as a predictor of survival in melanoma patients receiving immunotherapy D. Schrama, S. Ugurel, M. Zapatka, J. C. Becker |
| P10 | Interleukin 21-based stimulation can induce human B cells to secrete Granzyme B and gain cytotoxic potential B. Jahrsdörfer, S. E. Blackwell and G. J. Weiner |
| P11 | Surface expression of endocytosis receptors and endocytotic properties of monocyte derived dendritic cells are modulated by cytokine supplementation M. Staudinger, M. Peipp, C. Kellner, M. Gramatzki, R. Repp |
| P12 | Characterization of granulocyte-mediated antibody-dependent cytotoxicity: Reactive oxygen intermediates, perforin, caspases, cell conjugate formation and membrane lipid exchange H. Horner, Y. Wachter, C. Frank, M. Herrmann, B. Stockmeyer |
| P13 | Long peptide vaccine-induced migration of HPV16 specific type 1 and 2 T-cells into the lesions of VIN III patients M. J. P. Welters, G. G. Kenter, M. J. G. Löwik, T. M. A. Berends-van der Meer, A. P. G. Vloon, J. W. Drijfhout, A. R. P. M. Valentijn, J. Oostendorp, G. J. Fleuren, R. Offringa, S. H. van der Burg and C. J. M. Melief |
| P14 | Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8+ CD62L(high)+ T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rγnull mice E. Distler, C. Wölfel, S. Köhler, M. Nonn, N. Kaus, E. Schnürer, R. G. Meyer, T. C. Wehler, C. Huber, T. Wölfel, U. F. Hartwig, W. Herr |
| P15 | Leukemia-associated antigens (LAAs) as biomarkers of survival in acute myeloid leukemia (AML) J. Greiner, L. Bullinger, J. Chen, K. Giannopoulos, K. Döhner, A. Schmitt, R. F. Schlenk, J. R. Pollack, H. Döhner, M. Schmitt |
| P16 | Characterization of Myeloid suppressor cells in patients with Hepatocellular carcinoma B. Höchst, L. Ormandy, T. Greten, F. Korangy |
| P17 | Development of a peptide-vaccine targeting ovarian carcinomas and their vasculature H. Hörzer, S. Stevanovic, A. Marmé, P. Altevogt, D. Wallwiener, B. Gückel |
| P18 | Chimerization of Murine Hybridoma Antibodies by Homologous Recombination S. Lüttgau, G. Moldenhauer, G. J Hämmerling, F. Breitling |
| P19 | Optimized peptide delivery to dendritic cells (DCs): Increased T cell stimulatory capacity by loading DCs with complexes of cationic, antigenic peptides and Poly I/C dsRNA H. Haenssle, P. Riedl, R. Schirmbeck, K. Zachmann, C. Neumann, J. Reimann |
| P20 | RHAMM/CD168-R3 peptide vaccination of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM) and chronic lymphatic leukemia (CLL) elicits immunological and clinical responses M. Schmitt, A. Schmitt, K. Giannopoulos, J. Chen, L. Li, P. Liebisch, M. Ringhoffer, P. Guillaume, G. Ritter, M. Rojewski, S. Gnjatic, H. Döhner, J. Greiner |
| P21 | target cell-restricted stimulation of the CD95 (APO-1/FAs) Death receptor with various Bispecific CD20XCD95 antibodies T. Otz, L. Große-Hovest, H.-G. Rammensee and G. Jung |
| P22 | Development of new antigen-loading strategies of DC for vaccination K. Birkholz, J. Dörrie, N. Schaft, M. Schwenkert, C. Kellner, E. Kämpgen, G. Fey, G. Schuler |
| P23 | Dendritic cell therapy of patients with hormone refractory prostate cancer R. Maier, R. de Giuli, J. Hering, M. Fopp, R. von Moos, C. Böhme, H.-P. Schmid, T. Cerny, S. Gillessen and B. Ludewig |
| P24 | A Murine pancreatic adenocarcinoma cell line is highly immunogenic and causes cell mediated and humoral immune responses F. Zhao, B. Vermeer, A. I. Garbe, M. P. Manns, F. Korangy, T. F. Greten |
| P25 | Successful maturation of HM 1.24-presenting DCs in multiple myeloma patients N. Schub, J. Catalcali, M. Staudinger, B. Gahn, A. Humpe, R. Repp, M. Gramatzki |
| P26 | In-vitro-maturation of human monocyte-derived dendritic cells in presence of acid-treated gram-negative bacteria (R- and S-form) under serum-free conditions B. Hildenbrand, M. Azemar, B. Sauer, M. Zimmermann, S. F. Martin, M. Huber, D. Lorenzen, C. Unger, M. A. Freudenberg and C. Galanos |
| P27 | Highly purified R-form LPS from Salmonella in combination with IFN-γ enhance maturation and DC1-polarisation of human monocyte-derived dendritic cells under serum-free conditions B. Hildenbrand, M. Azemar, B. Sauer, M. Zimmermann, S. F. Martin, M. Huber, D. Lorenzen, C. Unger, M. A. Freudenberg and C. Galanos |
| P28 | Immunogenicity of FAPα-derived peptide epitopes in murine models V. Hofmeister, H. Voigt, R. Ullrich, J. C. Becker |
| P29 | Tumor antigen specific memory T cells in a transgenic mouse model of spontaneous melanoma O. Abschuetz, A. Figl, W. Osen, D. Schadendorf, V. Umansky |
| P30 | Tolerogenic dendritic cells in Ret-transgenic mouse model of spontaneous melanoma F. Zhao, D. Schadendorf, V. Umansky |
| P31 | Coordinated expression of clustered MAGEA and CSAG (TRAG-3) cancer/testis genes A. Bredenbeck, V. M Hollstein, U. Trefzer, W. Sterry, P. Walden and F. O Losch |
| P32 | Co-culture of human multicellular tumour spheroids (MCTS) and peripheral blood mononuclear cells (PBMC) with trifunctional antibodies T. Leidig, F. Wawrsinek and W. Mueller-Klieser |
| P33 | DNA vaccines in B-cell lymphoma D. Fioretti, S. Iurescia, E. Signori, G. Tonon, V. M. Fazio, M. Rinaldi |
| P34 | Phenotypes and functions of tumor-infiltrating lymphocytes in renal cell cancer patients S. Attig, J. Hennenlotter, A. Stenzl, S. Koch, G. Pawelec, H.-G. Rammensee, C. Gouttefangeas |
| P35 | Characterization of tumor-specific versus virus-specific tumor-infiltrating and peripheral T cells from melanoma patients S. Gross, U. Trefzer, W. Sterry and P. Walden |
| P36 | Serological mini-arrays for the analysis of humoral immune response to tumor-associated antigens Y. Shebzukhov, S. Khlgatian, A. Sazykin, P. Belousov, D. Kuprash and S. Nedospasov |
| P37 | Analysis of regulatory T cells in patients with multiple myeloma B. Hülsmann, U. Buttkereit, S. Ebert, K. Lennartz, M. Lindemann, W. Stellberg, D. Brandhorst, M. R. Nowrousian, P. Schütt, T. Moritz, B. Opalka |
| P38 | Identification of a novel CTL epitope from melanoma/melanocyte-specific protein, KU-MEL-1 E. Derhovanessian, V. S. Meyer, S. Stevanovic, S. Ugurel, D. Schadendorf, G. Pawelec |
| P39 | Uropathogenic E.coli but not commensale E.coli infection activates TLR-4 MyD independent signaling pathways in rat testicular cells S. Bhushan, S. Tchatalbachev, J. Klug, T. Chakraborty, C. Pineau, A. Meinhardt |
| P40 | Characterization of MUC-1 specific T-cells in breast cancer patients and healthy donors A.-C. Bậgu, S. Kayser, S. Stevanović, A. Marmé, I. Gruber, D. Wallwiener, S. Attig, B. Gückel |
| P41 | HSP70-antigen fusion proteins in combination with TLR ligands are efficient tumor vaccines B. Marincek, G. J. Hämmerling, F. Momburg |
| P42 | A comprehensive comparison of PGE2-matured and poly(I:C)-matured DC reveals differences in cytokine and IDO expression but comparable T cell-stimulating abilities I. Möller, N. Frech, H. Veelken, A.-K. T.-Kaskel |
| P43 | Recognition of methylated peptides by tumour-specific T cells in melanoma patients S. Jarmalavicius and P. Walden |
| P44 | Detection of IL2, CD25, and CD64 mRNA from spheroids co-cultured with PBMC and treated with trifunctional antibody catumaxomab B. Rodday, T. Leidig, S. Walenta and W. Mueller-Klieser |
| P45 | Shared MHC class I epitopes prevent T cell responses against unique tumor antigens through in situ activation of regulatory T cells in experimental antitumor vaccination M. Buchner, M. Warncke, H. Veelken |
| P46 | Activation of tumor specific T and B lymphocytes after radiofrequency ablation in cancer patients M. Widenmeyer, S. P. Haen, Y. Shebzukhov, S. Clasen, D. Schmidt, A. Stenzl, H.-G. Rammensee, P. L. Pereira, C. Gouttefangeas |
| P47 | WT-1 peptide vaccination after allogenic stem cell transplantation for patients with myeloid malignancies C. Gentilini, A. Müßig, A. Letsch, A. Asemissen, K. Rieger, C. Scheibenbogen, E. Thiel, L. Uharek |
| P48 | Characterisation of WT1-specific T cell responses in Peripheral Blood and Bone Marrow in leukemia patients vaccinated with WT1 peptide, GM-CSF, and KLH A. Letsch, U. Keilholz, A. Busse, A. M. Asemissen, A. Schmittel, W.-K. Hofmann, L. Uharek, I. W. Blau, E. Thiel, C. Scheibenbogen |
| P49 | Phase I clinical trial: Adoptive transfer of in vitro expanded tumor specific autologous T cells in patients with advanced ovarian cancer A. Wiernik, C.-C. Johansson, I. Poschke, L. Adamson, K. Bergfeldt, G. Masucci, R. Kiessling |
| P50 | CD 40 ligation during dendritic cell maturation reduces cell death and prevents IL-10 induced regression to macrophage-like monocytes T. Buhl, H. Haenssle, S. Bram, U. Krueger, K. Reich, C. Neumann |
| P51 | Polymorphism in genes coding for molecules associated with antitumor immune response in malignant melanoma and prostate cancer E. Naumova, G. Gaudernack, A. Mihaylova, S. Mihaylova, M. Ivanova, E. M. Inderberg Suso, D. Baltadjieva |
| P52 | Type I interferons are critical in the control T cell responses induced by dendritic cells activated by combined Toll-like receptor ligation T. Warger, P. Osterloh, G. Rechtsteiner, U. Kalinke, T. Bopp, H. Schild, M P Radsak |
| P53 | Analysis of the immunogenicity of a FLT3 internal tandem duplication (FLT3-ITD) C. Graf, F. Heidel, S. Tenzer, M. P. Radsak, F. K. Solem, C. M. Britten, C. Huber, T. Fischer and T. Wölfel |
| P54 | Expression and immune-inhibitory function of MIF in ovarian cancer M. Krockenberger, Y. Dombrowski, C. Weidler, M. Ossadnik, J. Wischhusen |
| P55 | A shift in the intestinal microflora towards pro-inflammatory bacteria and signaling via toll-like receptors 2 and 4 trigger early onset of Graft-versus-Host disease A. Nogai, M. M. Heimesaat, S. Bereswill, E. Thiel, U. B. Göbel, L. Uharek |
| P56 | Anti tumor vaccines based on stabilized mRNA (RNActive®) M. Fotin-Mleczek, B. Scheel, I. Hoerr and J. Probst |
| P57 | Generation of an improved recombinant bispecific antibody molecule and B7 fusion proteins for targeted cancer immunotherapy D. Müller, B. Meißburger, K. Frey, A. Karle, I. Höfig, R. Stork and R. E. Kontermann |
| P58 | The pharmaceutical formulation of peptide antigens and of toll like receptor (TLR-) agonists and the route of antigen delivery determines the strength of an antigen specific CD8+ T cell response A. Konur, A. Graser, I. Klamp, S. Kreiter, A. Selmi, M. Diken, C. Huber, U. Sahin |
| P59 | Cytotoxic T-cell mediated killing of cancer cells: The importance of the target epitope R. Baek Sørensen, A. Kirkin, H. Voigt, I. M. Svane, J. C. Becker, P. thor Straten, M. H. Andersen |
| P60 | Efficient tumor cell lysis mediated by a Bcl-X(L) specific T-cell clone isolated from a breast cancer patient R. Baek Sørensen, S. Reker, T. Køllgaard, I. M. Svane, M. H. Andersen, P. thor Straten |
| P61 | Spontaneous Immune Responses and Antigen expression in Patients with Acute Myeloid Leukemia T. Køllgaard, S. R. Hadrup, O. Juul, T. Seremet, M. H. Andersen, P. thor Straten |
| P62 | The 1 ml immunoscope: a rapid and robust FACS based assay for the identification and enumeration of lymphocyte populations G. Ioannidis, J. Stasakova, A. Williams, C. Ottensmeier |
| P63 | Memory CD8+ T cells mediate antibacterial immunity via CCL3 activation of TNF/ROI+ phagocytes E. Narni-Mancinelli, L. Campisi, D. Bassand, J. Cazareth, P. Gounon, N. Glaichenhaus and G. Lauvau |
Download:
Final-Program 2007 as PDF-file (1,3 MB)
